Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 4

Conditions: Allergic Conjunctivitis

Treatments: Drug: Pataday; Drug: Elestat

Study type: Interventional

Funder types: Industry

Identifiers

NCT00534794

031-408

Details and patient eligibility

About

The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.

Enrollment: 79 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented history of ocular allergy to cats.
• Positive skin prick allergen reaction to cat dander.

Exclusion criteria

• Use of any topical or systemic corticosteroids, immunosuppressive agents, antihistamines, decongestants, NSAIDs, or asprin during the two weeks prior to enrollment into the study.
• History of severe asthma, reactive airway disease or bronchial obstruction.
• Ocular surgery or trauma in the last year.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

79 participants in 2 patient groups

Elestat

Experimental group

Treatment:

Drug: Elestat

Pataday

Active Comparator group

Treatment:

Drug: Pataday